PRPHOTCPharmaceutical PreparationsFiscal year ends December 31
ProPhase Labs, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026
$0.01−0.00 (-6.16%)
Close on Oct 19, 2026
- Market cap
- $119.68K
- P/E (TTM)
- –
- Dividend yield
- –
ProPhase Labs, Inc. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Consumer Products Segment [Member] | $1.01M | $1.17M | – | $883.00K | $1.25M | $1.43M | – | $1.42M | $1.50M | $2.36M | – | $5.87M | 100.0% | -18.9% |
| Consumer products | – | – | – | – | – | – | – | – | $2.47M | $3.63M | $3.50M | $5.87M | – | – |
| Diagnostic Services [Member] | – | – | – | – | – | – | – | – | $0 | $0 | $0 | $2.49M | – | – |
| Diagnostic Services Segment [Member] | – | – | – | $0 | $0 | $0 | – | $0 | $0 | $0 | – | $2.49M | – | – |
By product or service
By region
From the segment and revenue-disaggregation notes of ProPhase Labs's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.